Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980849 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL980258 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL983036 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL980131 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL1109718 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL352158 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL982550 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL981238 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL983048 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB | |
| SCHEMBL981112 | 0.97 | TSHR (0.40) | TSHRLPAR2LPAR3LPAR1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116199612-B | Porous adsorbent and preparation method and application thereof | 荆楚理工学院 | 2024-06-21 | — | — | CN | claimed |
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-04-16 | — | — | US | claimed |
| CN-116199612-A | Porous adsorbent and preparation method and application thereof | 荆楚理工学院 | 2023-06-02 | — | — | CN | claimed |
| US-20200079801-A1 | TRISUBSTITUTEDSILYLBENZYLBENZIMIDAZOLES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-03-12 | — | — | US | claimed |
| EP-3619220-A1 | TRISUBSTITUTEDSILYLBENZYLBENZIMIDAZOLES AND ANALOGUES | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | claimed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | claimed |
| WO-2018202715-A1 | TRISUBSTITUTEDSILYLBENZYLBENZIMIDAZOLES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | WO | claimed |
| US-9040648-B2 | Polymer compositions containing mechanochromic polymers | PPG INDUSTRIES OHIO, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-8889807-B2 | Controlled radical polymerization initiators | PPG INDUSTRIES OHIO, INC. (US) | 2014-11-18 | — | — | US | claimed |
| WO-2014152259-A1 | POLYMER COMPOSITIONS CONTAINING MECHANOCHROMIC POLYMERS | PPG INDUSTRIES OHIO, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-6204354-B1 | DRY ENVIRONMENT | BRIDGESTONE CORPORATION (JP) | 2001-03-20 | — | — | US | claimed |
| US-6191217-B1 | REACTING POLY(ALKYL VINYLETHER-CO-MALEIMIDE) POLYMER WITH MALEATED POLYALKYLENE AND ALKYL DIAMINE UNDER SUBSTANTIALLY DRY CONDITIONS SUFFICIENT TO FORM POLYALKYLENE GRAFTED POLY(ALKYL VINYLETHER-CO-MALEIMIDE) POLYMER | BRIDGESTONE CORPORATION (JP) | 2001-02-20 | — | — | US | claimed |
| US-6133354-A | MIXING A POLY(DIALKYLSUBSTITUTED ETHYLENE-CO-MALEIMIDE) POLYMER SUCH AS POLYISOBUTYLENE-CO-MALEIMIDE, AND PLASTICIZERS OR EXTENDERS WITHIN A NON-VULCANIZED THERMOPLASTIC ELASTOMER TO FORM A DAMPING GEL; TENSILE STRENGTH AND TEAR STRENGTH | BRIDGESTONE CORPORATION (JP) | 2000-10-17 | — | — | US | claimed |
| EP-0955319-A1 | Soft compounds derived from polypropylene grafted disubstituted ethylene-maleimide copolymers | Bridgestone Corporation (JP) | 1999-11-10 | — | — | EP | claimed |
| US-5773421-A | Antifungal fusacandins | ABBOTT LABORATORIES (US) | 1998-06-30 | — | — | US | claimed |
| EP-0802920-A2 | ANTIFUNGAL FUSACANDINS | Abbott Laboratories (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1996021670-A2 | ANTIFUNGAL FUSACANDINS | ABBOTT LABORATORIES (US) | 1996-07-18 | — | — | WO | claimed |
| EP-0254078-B1 | PYRAN DERIVATIVES | BASF Aktiengesellschaft (DE) | 1991-02-06 | — | — | EP | claimed |
| EP-0254078-A1 | Pyran derivatives | BASF Aktiengesellschaft (DE) | 1988-01-27 | — | — | EP | claimed |
| CN-85108210-A | Preparation A80190 antibiotic method | — | 1986-12-03 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | GMPS, GLS, QPCT | TSHR 4604/4885ALDH1A1 3726/4885LPAR2 2030/4885 |
| US-20200079801-A1 | TRISUBSTITUTEDSILYLBENZYLBENZIMIDAZOLES AND ANALOGUES | PIK3C3, DPM1, ERG28 | TSHR 4552/4885ALDH1A1 2607/4885LPAR2 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.